ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1690

FAPI-PET/CT as a Predictor of Accelerated Lung Function Deterioration in Systemic Sclerosis Related Interstitial Lung Disease (ILD): Preliminary-interim Analysis from a Confirmatory Risk Factor Study
Abstract Number: 0352

Fast-tracking Axial Spondyloarthritis Diagnosis: A Novel Approach to Public Health Advocacy and Awareness
Abstract Number: 0053

Fasting Reduces an IL-17+/IFNg+ T Helper Cell-inducing Gut Pathobiont in Patients with Rheumatoid Arthritis
Abstract Number: 2329

Feasibility of a Streamlined Approach for Psoriatic Arthritis Screening and Symptom Assessment
Abstract Number: 2228

Feasibility, Safety, and Application for Clinical Indication and Research Purposes of Synovial Tissue Analysis in Rheumatoid Arthritis
Abstract Number: 2447

Features of Anti-Fibrillarin Positive Systemic Sclerosis Patients and Ethnic Differences: A European Multicenter Cohort
Abstract Number: 1997

Features of interleukin-1 and interleukin-6 Inhibitor (IL-1i/IL-6i) Related Severe Delayed Adverse Reactions in Subjects with or Without Reaction-risk Associated HLA-DRB1*15
Abstract Number: 2165

Fertility Concerns in Adolescents and Young Adults Receiving Gonadotoxic Medications for Rheumatic Disease
Abstract Number: 2298

Fibroblast-driven Ttek Activation May Drive Acinar Cell Dysfunction in Sjögren’s Disease, Prior to Lymphocytic Infiltration
Abstract Number: 2292

Fibroblasts with High Expression of CD74 Promote Lymphocytes Infiltration in Salivary Gland in Sjӧgren’s Disease
Abstract Number: 1225

Fibromyalgia as a Potential Initial Presentation for Autoimmune Conditions
Abstract Number: 1220

Fibromyalgia’s Under-Representation in Rheumatology Literature: A Ten-Year Analysis of Disease-Specific Article Distribution
Abstract Number: 1332

Financial Distress and Its Determinants in Adults with Rheumatoid Arthritis
Abstract Number: PP09

Finding the Balance: Regaining My Strength While Living with Sjögren’s & POTS
Abstract Number: 0786

First Analyses of Transcriptomic Changes in the Skin of SSc Patients upon CD19-targeting CAR T Cell Therapy

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].